• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

Interview with Shobha Dhadda

2016-07-29News

What is your current role in EPAD?

I am one of the leaders of Work package 2 as well as a steering committee member. Work package 2 is responsible for creation of the disease models and adaptive design platform trial. In addition, I contributed to the development of proof of concept protocol with work package 4. This collaboration is multi-level and extends to almost all the work packages on development of regulatory strategy, on the endpoints/biomarkers for the POC trial, on data base development etc.

What did you do prior to joining EPAD?

I am a global head of Biostatistics and project operations of Neurology Business group at Eisai responsible for statistical methods, supporting regulatory and clinical development strategies, and operational aspects of all global drug development projects. I have been working in the Pharmaceutical Industry for more than twenty years. I started my career at Searle/Pharmacia and then worked at Astellas for ten years before joining Eisai in 2012 as the head of Biostatistics. Utilizing innovative statistical designs to increase efficiency of clinical trials and thus speed up the availability of new medicines to patients is my passion. I have worked on five Bayesian adaptive design clinical trials and thus understand the scientific, operational, business and regulatory challenges. Two of these Bayesian adaptive design trials are currently ongoing at Eisai and one is completed.

Tell us a bit about your organisation.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, manufacturing and marketing capabilities.  We have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs. Eisai is the first company to utilize Bayesian adaptive design in an Alzheimers clinical trial. That’s why it is a natural extension for Eisai to be part of EPAD family.

What are your expectations from the EPAD project?

Many of the pharma companies in the Alzheimers dementia area have been starting large phase 3 clinical trials without first performing adequate proof of concept trials. EPAD is a unique opportunity for companies in this space to test their drugs on the EPAD platform before embarking on large phase 3 trials. It utilizes the Bayesian adaptive design allowing for sharing of placebos across the drugs thus maximizing the probability of success. One of the major challenges for clinical trials in early dementia has been the ability to find the right patients, with the screen failure rates as high as 75% to 85%. It will be an even bigger challenge to find the pre-dementia study volunteers. I am excited about the longitudinal cohort study that would deliver 6000 research participants at any given time.  I think this collaboration across different work packages with experts in every field working together to address prevention of dementia will be a standard model for other difficult disease areas.

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Edinburgh Dementia Prevention Summer School 2022
2022-06-30
EPAD at AAIC22!
2022-06-30
ADDI NeuroToolKit Data Hackathon
2022-05-17
The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
2022-05-09
First national follow-on study to EPAD LCS launches
2022-04-07
The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
2022-03-10
Latest News
  • Edinburgh Dementia Prevention Summer School 2022
    2022-06-30
  • EPAD at AAIC22!
    2022-06-30
  • ADDI NeuroToolKit Data Hackathon
    2022-05-17
  • The Neuronet Coordination and Support Action releases updated Decision Tool for engagement with Regulatory and Health Technology Assessment bodies
    2022-05-09
  • First national follow-on study to EPAD LCS launches
    2022-04-07
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

The @CenDemPrevent Summer School, a 4-day interactive course on #brainhealth, is designed for clinicians, researchers and students. Space is limited, sign up quickly! 🗓️26-29 September 📍Edinburgh For more info, including programme⤵️ ep-ad.org/edinburgh-deme… pic.twitter.com/FSypbvWK4L

reply retweet favorite
12:38 pm · 2022-06-30
Twitter
EPAD
EPAD
@IMI_EPAD

There’s still time to join the @AlzData #NeuroToolKit #Data Hackathon! Registration closes on 24 June! Participants will work with @IMI_EPAD datasets and utilise the tools on the #ADWorkbench. Interested in participating? ➡️alzheimersdata.org/hackathon twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:21 am · 2022-06-22
Twitter
EPAD
EPAD
@IMI_EPAD

Today, colleagues from @AlzData visited @CenDemPrevent to meet with those involved in various programmes including @IMI_EPAD @AD_PREVENT. Many relevant discussions and great catch-up! #BrainHealth #datasharing #collaboration @craig_ritchie68 @samdansobe @GregorySarah @CindyBirck pic.twitter.com/Mr3trKeuoz

reply retweet favorite
2:43 pm · 2022-06-15
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the new @AlzheimerEurope #DementiaInEurope magazine featuring an article on @IMI_EPAD and its collaboration with @AlzData to make our data findable, accessible and reusable. @craig_ritchie68 ⤵️ alzheimer-europe.org/resource… twitter.com/AlzheimerEurop… pic.twitter.com/vLuW3HMLUh

reply retweet favorite
1:09 pm · 2022-06-14
Twitter
EPAD
EPAD
@IMI_EPAD

Registration will close tomorrow! Register now for the free #Brainhealth2022 conference, taking place next week in Edinburgh ⤵️ brainhealth.scot/brainhealth2… twitter.com/IMI_EPAD/statu…

reply retweet favorite
3:05 pm · 2022-06-09
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT